HSR | Jotup

Next-Generation Family of Ethernet Switches Features Time Sensitive Networking and Scalable Port Bandwidths from 46 Gbps to 102 Gbps

Retrieved on:

Tuesday, January 16, 2024

To provide designers with a reliable and robust network solution with deterministic communication, Microchip Technology (Nasdaq: MCHP) today announces its next-generation of LAN969x Ethernet switches with Time Sensitive Networking (TSN), scalable bandwidths from 46 Gbps to 102 Gbps and a powerful 1 GHz single-core Arm® Cortex®-A53 CPU.

Key Points:

To provide designers with a reliable and robust network solution with deterministic communication, Microchip Technology (Nasdaq: MCHP) today announces its next-generation of LAN969x Ethernet switches with Time Sensitive Networking (TSN), scalable bandwidths from 46 Gbps to 102 Gbps and a powerful 1 GHz single-core Arm® Cortex®-A53 CPU.
For applications that require greater redundancy, the LAN969x Ethernet switches can be configured with High-availability Seamless Redundancy (HSR) and Parallel Redundancy Protocol (PRP).
“Prior to the introduction of Microchip’s LAN969x Ethernet switches, customers who wanted to implement TSN and HSR/PRP features required multiple ICs.
The new family of LAN969x mid-range Ethernet switches rounds out Microchip’s portfolio of TSN switches.

FTC, DOJ Issue Fiscal Year 2022 Hart-Scott-Rodino Notification Report

Retrieved on:

Wednesday, January 3, 2024

Federal Trade Commission, Annual report, Health, Justice, Blog, Congress, News, Federation, DOJ, FTC, Social media, HSR, Commission, Cryptocurrency

The agencies’ 45th Annual Hart-Scott-Rodino Report notes that in fiscal year 2022, 3,152 transactions were reported under the HSR Act, which is the second-highest number of reported transactions over the past 10 years.

Key Points:

The agencies’ 45th Annual Hart-Scott-Rodino Report notes that in fiscal year 2022, 3,152 transactions were reported under the HSR Act, which is the second-highest number of reported transactions over the past 10 years.
The number of second requests issued by the agencies in fiscal year 2022 is consistent with the average number of second requests issued across the last decade.
The FTC and DOJ together filed 50 merger enforcement actions in fiscal year 2022, representing the highest level of enforcement activity in over 20 years.
The report includes statistical tables profiling HSR filings and investigations during fiscal year 2022.

FTC, DOJ Issue Fiscal Year 2022 Hart-Scott-Rodino Notification Report

Retrieved on:

Wednesday, January 3, 2024

Federal Trade Commission, Annual report, Health, Justice, Blog, Congress, News, Federation, DOJ, FTC, Social media, HSR, Commission, Cryptocurrency

The agencies’ 45th Annual Hart-Scott-Rodino Report notes that in fiscal year 2022, 3,152 transactions were reported under the HSR Act, which is the second-highest number of reported transactions over the past 10 years.

Key Points:

The agencies’ 45th Annual Hart-Scott-Rodino Report notes that in fiscal year 2022, 3,152 transactions were reported under the HSR Act, which is the second-highest number of reported transactions over the past 10 years.
The number of second requests issued by the agencies in fiscal year 2022 is consistent with the average number of second requests issued across the last decade.
The FTC and DOJ together filed 50 merger enforcement actions in fiscal year 2022, representing the highest level of enforcement activity in over 20 years.
The report includes statistical tables profiling HSR filings and investigations during fiscal year 2022.

Veea to Become Publicly Traded Company via proposed Business Combination with Plum Acquisition Corp. I

Retrieved on:

Tuesday, November 28, 2023

NEW YORK, NY and SAN FRANCISCO, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Veea Inc. (“Veea” or the “Company”), a digital transformation company, and Plum Acquisition Corp.

Key Points:

NEW YORK, NY and SAN FRANCISCO, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Veea Inc. (“Veea” or the “Company”), a digital transformation company, and Plum Acquisition Corp.
I (“Plum”, and together, the “Parties”) (Nasdaq: PLMI), a Cayman Islands exempted company formed as a special purpose acquisition company by Ursula Burns, Kanishka Roy and Mike Dinsdale, today announced their entry into a definitive business combination agreement (the “Business Combination Agreement”) related to a proposed merger (such merger and related transactions, including the issuance by Plum of securities in connection therewith, collectively, the “Business Combination”) expected to result in Veea becoming a publicly traded company (referred to herein as the “Combined Company” ) whose business, after the closing (the “Closing”), assuming the occurrence thereof, will be the continued business of Veea.
Proceeds from the proposed Business Combination and financing transactions are expected to support the Combined Company in its business plans, including Veea’s mission of positioning itself as a leader of Digital Inclusion across the globe.
The proposed Business Combination has, prior to the execution of the Business Combination Agreement, been approved by the boards of directors of each of Veea and Plum.

GMS to Acquire Kamco Supply Corporation

Retrieved on:

Thursday, December 21, 2023

GMS Inc. (NYSE: GMS), a leading North American specialty building products distributor, today announced that it has entered into an agreement to acquire Kamco Supply Corporation and affiliates (“Kamco” or the “Company”).

Key Points:

GMS Inc. (NYSE: GMS), a leading North American specialty building products distributor, today announced that it has entered into an agreement to acquire Kamco Supply Corporation and affiliates (“Kamco” or the “Company”).
The transaction is expected to close during the fourth quarter of fiscal 2024 for GMS, which ends on April 30, 2024.
John C. Turner, Jr., President, and Chief Executive Officer of GMS, said, “Kamco is a long-established leader in the building materials industry with an experienced and successful team.
GMS expects to capitalize on cross-selling opportunities with Kamco and GMS’s other operations in the region, including the recently acquired Tanner Bolt and Nut, Inc. business.

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

Retrieved on:

Monday, December 11, 2023

The agreement was originally announced in May 2023 with closing subject to review under the Hart-Scott-Rodino (HSR) Act.

Key Points:

The agreement was originally announced in May 2023 with closing subject to review under the Hart-Scott-Rodino (HSR) Act.
“At Maze, our commitment is to the patients around the world that we believe can benefit from our work.
With positive preclinical and Phase 1 data, MZE001 has the potential to be the first oral therapeutic option to address Pompe disease, providing a new option for patients suffering from Pompe disease.
Maze’s second undisclosed program in chronic kidney disease is scheduled to commence clinical trials in the second half of 2024.

CF Industries Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Waggaman Ammonia Production Facility Acquisition

Retrieved on:

Wednesday, November 15, 2023

Agriculture, Natural Resources, Sustainability, Environment, Alternative Energy, Energy, Chemicals, Plastics, Manufacturing, Dyno Nobel, Hand, Economics, CF Industries, NYSE, HSR, IPL, Hart–Scott–Rodino Antitrust Improvements Act, Ammonia

CF Industries Holdings, Inc. (NYSE: CF) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), in connection with its previously announced agreement to purchase Incitec Pivot Limited’s (“IPL”) ammonia production complex located in Waggaman, Louisiana.

Key Points:

CF Industries Holdings, Inc. (NYSE: CF) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), in connection with its previously announced agreement to purchase Incitec Pivot Limited’s (“IPL”) ammonia production complex located in Waggaman, Louisiana.
The expiration of the HSR Act waiting period was a condition to the closing of the pending transaction.
CF Industries and IPL expect to complete the transaction effective December 1, 2023, subject to the satisfaction of other customary closing conditions.
Under the terms of the agreement, CF Industries will purchase the Waggaman ammonia plant and related assets for $1.675 billion.

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Retrieved on:

Monday, November 6, 2023

HSR, ESMO, VHH, BioNTech, Inflammation, Hart–Scott–Rodino Antitrust Improvements Act, Immunoglobulin G, Tumor microenvironment, Safety, Patient, Toxicity, FC, Pharmaceutical industry

ZHUHAI, China, Nov. 6, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China. PM8002 is currently being tested in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors.

Key Points:

PM8002 is currently being tested in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors.
The transaction is expected to close in Q4 2023, subject to customary closing conditions, including clearance under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act, and regulatory clearances.
PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations.
"Biotheus' innovative platform has the capability to expedite preclinical research, bolstering our impressive innovative pipeline of products with encouraging efficacy and safety including PM8002.

TPG Completes Acquisition of Angelo Gordon

Retrieved on:

Thursday, November 2, 2023

TPG Inc. (NASDAQ: TPG), a leading global alternative asset management firm, today announced the successful completion of its previously announced acquisition of Angelo Gordon.

Key Points:

TPG Inc. (NASDAQ: TPG), a leading global alternative asset management firm, today announced the successful completion of its previously announced acquisition of Angelo Gordon.
Moving forward, Angelo Gordon will operate as TPG Angelo Gordon, a $74 billion[1] diversified credit and real estate investing platform within TPG.
“As we continue to operate and invest in dynamic markets, the addition of Angelo Gordon expands our capabilities and creates highly compelling investment opportunities.
Goldman Sachs & Co. LLC and Piper Sandler acted as financial advisor to Angelo Gordon and Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel.

Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc.

Retrieved on:

Thursday, October 26, 2023

The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tender offer.

Key Points:

The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tender offer.
Other customary offer conditions remain to be satisfied, including, among others, a minimum tender of at least a majority of outstanding Intercept common stock.
Any forward-looking statements in this release are based upon information known to Alfasigma on the date of this announcement.
Neither Alfasigma nor Intercept undertakes any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.